Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 2.19 MB
Add to list
  1. Search results
  2. Anti-neuraminidase and anti-hemagglut...

Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B

João Portela Catani (UGent) , Tine Ysenbaert (UGent) , Anouk Smet (UGent) , Marnik Vuylsteke, Thorsten U. Vogel and Xavier Saelens (UGent)
(2023) PLOS ONE. 18(1).
Author
Organization
Abstract
Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.
Keywords
Multidisciplinary, VIRUS NEURAMINIDASE, REASSORTMENT, ANTIBODIES, RESISTANCE, INFECTION

Downloads

  • Download
    Catani et al anti-NA and anti-HA serum confer inter-lineage protection against IBV Plos One 2023.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 2.19 MB

Citation

Please use this url to cite or link to this publication:

MLA
Portela Catani, João, et al. “Anti-Neuraminidase and Anti-Hemagglutinin Immune Serum Can Confer Inter-Lineage Cross Protection against Recent Influenza B.” PLOS ONE, edited by Victor C. Huber, vol. 18, no. 1, 2023, doi:10.1371/journal.pone.0280825.
APA
Portela Catani, J., Ysenbaert, T., Smet, A., Vuylsteke, M., Vogel, T. U., & Saelens, X. (2023). Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B. PLOS ONE, 18(1). https://doi.org/10.1371/journal.pone.0280825
Chicago author-date
Portela Catani, João, Tine Ysenbaert, Anouk Smet, Marnik Vuylsteke, Thorsten U. Vogel, and Xavier Saelens. 2023. “Anti-Neuraminidase and Anti-Hemagglutinin Immune Serum Can Confer Inter-Lineage Cross Protection against Recent Influenza B.” Edited by Victor C. Huber. PLOS ONE 18 (1). https://doi.org/10.1371/journal.pone.0280825.
Chicago author-date (all authors)
Portela Catani, João, Tine Ysenbaert, Anouk Smet, Marnik Vuylsteke, Thorsten U. Vogel, and Xavier Saelens. 2023. “Anti-Neuraminidase and Anti-Hemagglutinin Immune Serum Can Confer Inter-Lineage Cross Protection against Recent Influenza B.” Ed by. Victor C. Huber. PLOS ONE 18 (1). doi:10.1371/journal.pone.0280825.
Vancouver
1.
Portela Catani J, Ysenbaert T, Smet A, Vuylsteke M, Vogel TU, Saelens X. Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B. Huber VC, editor. PLOS ONE. 2023;18(1).
IEEE
[1]
J. Portela Catani, T. Ysenbaert, A. Smet, M. Vuylsteke, T. U. Vogel, and X. Saelens, “Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B,” PLOS ONE, vol. 18, no. 1, 2023.
@article{01H3CM7GE51A9FAM9NRFQYQ05E,
  abstract     = {{Influenza B viruses (IBV) are responsible for a considerable part of the burden caused by influenza virus infections. Since their emergence in the 1980s, the Yamagata and Victoria antigenic lineages of influenza B circulate in alternate patterns across the globe. Furthermore, their evolutionary divergence and the appearance of new IBV subclades complicates the prediction of future influenza vaccines compositions. It has been proposed that the addition of the neuraminidase (NA) antigen could potentially induce a broader protection and compensate for hemagglutinin (HA) mismatches in the current vaccines. Here we show that anti-NA and -HA sera against both Victoria and Yamagata lineages have limited inter-lineage cross-reactivity. When transferred to mice prior to infection with a panel of IBVs, anti-NA sera were as potent as anti-HA sera in conferring protection against homologous challenge and, in some cases, conferred superior protection against challenge with heterologous IBV strains.}},
  articleno    = {{e0280825}},
  author       = {{Portela Catani, João and Ysenbaert, Tine and Smet, Anouk and Vuylsteke, Marnik and Vogel, Thorsten U. and Saelens, Xavier}},
  editor       = {{Huber, Victor C.}},
  issn         = {{1932-6203}},
  journal      = {{PLOS ONE}},
  keywords     = {{Multidisciplinary,VIRUS NEURAMINIDASE,REASSORTMENT,ANTIBODIES,RESISTANCE,INFECTION}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{16}},
  title        = {{Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B}},
  url          = {{http://doi.org/10.1371/journal.pone.0280825}},
  volume       = {{18}},
  year         = {{2023}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: